Targeting VE-PTP phosphatase protects the kidney from diabetic injury
Isabel A. Carota,Yael Kenig-Kozlovsky,Tuncer Onay,Rizaldy Scott,Benjamin R. Thomson,Tomokazu Souma,Christina S. Bartlett,Yanyang Li,Daniele Procissi,Veronica Ramirez,Shinji Yamaguchi,Antoine Tarjus,Christine E. Tanna,Chengjin Li,Vera Eremina,Dietmar Vestweber,Sunday S. Oladipupo,Matthew D. Breyer,Susan E. Quaggin
DOI: https://doi.org/10.1084/jem.20180009
2019-03-18
Abstract:Diabetic nephropathy is a leading cause of end-stage kidney failure. Reduced angiopoietin-TIE2 receptor tyrosine kinase signaling in the vasculature leads to increased vascular permeability, inflammation, and endothelial cell loss and is associated with the development of diabetic complications. Here, we identified a mechanism to explain how TIE2 signaling is attenuated in diabetic animals. Expression of vascular endothelial protein tyrosine phosphatase VE-PTP (also known as PTPRB), which dephosphorylates TIE2, is robustly up-regulated in the renal microvasculature of diabetic rodents, thereby reducing TIE2 activity. Increased VE-PTP expression was dependent on hypoxia-inducible factor transcriptional activity in vivo. Genetic deletion of VE-PTP restored TIE2 activity independent of ligand availability and protected kidney structure and function in a mouse model of severe diabetic nephropathy. Mechanistically, inhibition of VE-PTP activated endothelial nitric oxide synthase and led to nuclear exclusion of the FOXO1 transcription factor, reducing expression of pro-inflammatory and pro-fibrotic gene targets. In sum, we identify inhibition of VE-PTP as a promising therapeutic target to protect the kidney from diabetic injury.
immunology,medicine, research & experimental